A novel side-chain-linked antiparallel cyclic dimer of enkephalin

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Peptide Synthesis

Background:

• Enkephalins are endogenous opioid peptides involved in pain modulation and reward pathways.
• Modulating enkephalin activity is a key strategy for developing novel analgesics and therapeutics.
• Cyclic analogs of enkephalins have shown altered receptor binding and pharmacological profiles.

Purpose of the Study:

• To synthesize and characterize a dimeric cyclic enkephalin analog.
• To investigate the opioid receptor selectivity of the synthesized cyclic enkephalin dimer.
• To explore the potential of cyclodimerization as a method for altering peptide activity profiles.

Main Methods:

• Solid-phase synthesis was employed to produce the cyclic enkephalin monomer and dimer.
• The dimeric analog was isolated as a major component from the crude synthetic product.
• Opioid receptor binding assays were conducted to determine receptor selectivity (mu and delta).

Main Results:

• The dimeric cyclic enkephalin analog, (H-Tyr-D-Lys-Gly-Phe-Glu-NH2)2, was successfully synthesized.
• The dimer exhibited equipotency at mu-opioid receptors compared to [Leu5]enkephalin.
• The dimer showed reduced potency (1/10) at delta-opioid receptors compared to [Leu5]enkephalin.

Conclusions:

• The dimeric cyclic enkephalin analog displays a unique receptor selectivity profile.
• Cyclodimerization via side-chain linkages offers a novel approach to modulate peptide activity.
• This strategy may be broadly applicable for modifying the pharmacological profiles of peptide hormones and neurotransmitters.